# Bernstein Downgrades Summit Therapeutics to Underperform on R&D Concerns

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/60675
Published: 2026-11-18T17:29:46.000Z
Updated: 2026-11-18T17:29:46.000Z
Section: Investing

> The FDA declined to approve ivonescimab, Summit’s lead asset developed with partner Akeso in China.

Bernstein lowered its rating on Summit Therapeutics Inc. (NASDAQ: SMMT) to Underperform from Market Perform on Nov. 18, citing concern about the company’s research and development capabilities after the FDA declined to approve its lead asset, ivonescimab.

Summit developed ivonescimab with partner Akeso in China.


